- Home
- ARGX vs ZBH Comparison
ARGX vs ZBH Comparison
Compare ARGX & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- ZBH
- Stock Information
- Founded
- ARGX 2008
- ZBH 1927
- Country
- ARGX Netherlands
- ZBH United States
- Employees
- ARGX N/A
- ZBH N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- ZBH Industrial Specialties
- Sector
- ARGX Health Care
- ZBH Health Care
- Exchange
- ARGX Nasdaq
- ZBH Nasdaq
- Market Cap
- ARGX 33.0B
- ZBH N/A
- IPO Year
- ARGX 2017
- ZBH N/A
- Fundamental
- Price
- ARGX $555.96
- ZBH $93.97
- Analyst Decision
- ARGX Strong Buy
- ZBH Hold
- Analyst Count
- ARGX 17
- ZBH 21
- Target Price
- ARGX $730.07
- ZBH $112.74
- AVG Volume (30 Days)
- ARGX 447.4K
- ZBH 2.2M
- Earning Date
- ARGX 07-24-2025
- ZBH 08-07-2025
- Dividend Yield
- ARGX N/A
- ZBH 1.02%
- EPS Growth
- ARGX N/A
- ZBH N/A
- EPS
- ARGX 15.94
- ZBH 4.51
- Revenue
- ARGX $2,643,062,000.00
- ZBH $7,698,500,000.00
- Revenue This Year
- ARGX $61.64
- ZBH $7.65
- Revenue Next Year
- ARGX $32.00
- ZBH $5.63
- P/E Ratio
- ARGX $32.12
- ZBH $20.85
- Revenue Growth
- ARGX 82.13
- ZBH 3.30
- 52 Week Low
- ARGX $457.42
- ZBH $89.22
- 52 Week High
- ARGX $678.21
- ZBH $116.71
- Technical
- Relative Strength Index (RSI)
- ARGX 48.18
- ZBH 52.28
- Support Level
- ARGX $536.02
- ZBH $93.03
- Resistance Level
- ARGX $571.99
- ZBH $96.92
- Average True Range (ATR)
- ARGX 14.78
- ZBH 1.98
- MACD
- ARGX 2.30
- ZBH 0.31
- Stochastic Oscillator
- ARGX 74.12
- ZBH 53.24
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.